Bumrungrad Hospital PCL (BKK:BH)
| Market Cap | 135.14B |
| Revenue (ttm) | 25.49B |
| Net Income (ttm) | 7.57B |
| Shares Out | 794.97M |
| EPS (ttm) | 8.72 |
| PE Ratio | 19.50 |
| Forward PE | 18.21 |
| Dividend | 5.00 (2.92%) |
| Ex-Dividend Date | Mar 17, 2026 |
| Volume | 3,312,481 |
| Average Volume | 5,701,847 |
| Open | 171.00 |
| Previous Close | 171.00 |
| Day's Range | 169.00 - 171.50 |
| 52-Week Range | 130.00 - 214.00 |
| Beta | 0.17 |
| RSI | 48.35 |
| Earnings Date | Apr 23, 2026 |
About Bumrungrad Hospital PCL
Bumrungrad Hospital Public Company Limited owns and operates hospitals and healthcare centers in Thailand and internationally. It offers services in the areas of allergy, arrhythmia, behavioural health, breast, home, heart valve, robotic surgery, rehabilitation, spine, pediatrics, colorectal surgery, complex coronary artery intervention, comprehensive sleep, cornea transplant, dental, diagnostic, dialysis, radiology and nuclear medicine, digestive disease, ear, nose, throat, emergency, endocrinology, esperance, diabetes, expatriate liaison, eye... [Read more]
Financial Performance
In 2025, Bumrungrad Hospital PCL's revenue was 25.45 billion, a decrease of -1.60% compared to the previous year's 25.86 billion. Earnings were 7.51 billion, a decrease of -3.38%.
Financial StatementsNews
Q1 2026 Bumrungrad Hospital PCL Earnings Presentation (Pre-recorded) Transcript
Q1 2026 Bumrungrad Hospital PCL Earnings Presentation (Pre-recorded) Transcript
Q3 2025 Bumrungrad Hospital PCL Earnings Presentation (Pre-recorded) Transcript
Q3 2025 Bumrungrad Hospital PCL Earnings Presentation (Pre-recorded) Transcript
Bumrungrad Hospital PCL Earnings Call Transcript: Q3 2025
Q3 2025 delivered record margins and profit growth, driven by strong international patient demand, especially from the Middle East and South Asia, offsetting declines from China and Cambodia. Cash and investments rose, and the hospital remains on track with major expansion projects.
Bumrungrad Hospital PCL Earnings Call Transcript: Q2 2025
Q2 2025 revenue declined 3.6% year-over-year to THB 6,104 million, but EBITDA margin hit a record 41.6% due to strong cost control. Middle East patient volumes rebounded sequentially, while insurance revenue grew 12% YTD. Outlook for 2H 2025 is positive, with Q3 revenue guided up 3%-5%.
Bumrungrad Hospital PCL Earnings Call Transcript: Q1 2025
Q1 2025 revenue declined 5.6% year-over-year, mainly due to a 30% drop in Middle East revenue from Ramadan's early timing, while Thai patient revenue grew 1.2%. EBITDA and net profit both fell 12.6%, but cash and investments rose to THB 16 billion.
Former MP Akapol dies at 65
Former Democrat politician Akapol Sorasuchart died on Tuesday at the age of 65 at Bumrungrad Hospital.
Q4 2024 Bumrungrad Hospital PCL Earnings Presentation Transcript
Q4 2024 Bumrungrad Hospital PCL Earnings Presentation Transcript
Bumrungrad Hospital PCL Earnings Call Transcript: Q4 2024
Record-high net profit and margins in 2024, with 11% EPS growth and strong cash flow, offsetting Middle East revenue declines through diversified international and Thai/expat growth. VitalLife and insurance segments delivered robust results, and a record dividend is proposed.
Q3 2024 Bumrungrad Hospital PCL Earnings Presentation (Pre-recorded) Transcript
Q3 2024 Bumrungrad Hospital PCL Earnings Presentation (Pre-recorded) Transcript
Bumrungrad Hospital PCL Earnings Call Transcript: Q3 2024
Q3 2024 saw a 4.9% revenue decline and flat net profit, but margins remained strong due to cost control. Middle East patient revenue dropped sharply, while China and U.S. segments grew. CapEx plans and new projects, including the Phuket hospital, remain on track.
Bumrungrad Hospital PCL Earnings Call Transcript: Q2 2024
Q2 and 1H 2024 saw record-high margins and strong profit growth, driven by international diversification and cost management. Revenue from Qatar and China offset declines in Kuwait, while insurance and VitalLife segments posted robust gains.